Azione LYTIX LYTIX BIOPHARMA
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Lytix Biopharma

Azioni

LYTIX

NO0010405780

Mercato chiuso - Oslo Bors
Altri mercati azionari
 16:45:00 26/04/2024 		Variaz. 5gg Var. 1 gen.
5,72 NOK -1,04% Grafico intraday di Lytix Biopharma +7,92% +17,70%
25/04 Lytix Biopharma annuncia l'approvazione dello studio di Fase II nel tumore della pelle in fase precoce (melanoma), che rappresenta un'opportunità commerciale significativa CI
10/04 Lytix Biopharma raccoglierà fino a 55 milioni di corone norvegesi tramite un'offerta di azioni MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Lytix Biopharma AS - Share issue pursuant to board authorisation
Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates
Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity
Lytix Biopharma AS - Preliminary results in the share offering
Lytix Biopharma AS - Last day of the Application Period
Lytix Biopharma : CEO Presentation and Q&A with Redeye AB
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lytix Biopharma presents third quarter 2023 results
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November
Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023
Lytix Biopharma AS Announces Research Council of Norway Approves Lytix?s Application for Up to NOK 14.3 Million of Non-Dilutive Financial Support from the Skattefunn
Lytix Biopharma Secures NOK14.3 Million Research Grant for Skin Cancer Treatment
Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from 'SkatteFUNN'
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione LYTIX
  4. Notizie Lytix Biopharma
  5. Altre lingue